-
Je něco špatně v tomto záznamu ?
AF ablation using a novel "single-shot" map-and-ablate spherical array pulsed field ablation catheter: 1-Year outcomes of the first-in-human PULSE-EU trial
MK. Turagam, P. Neuzil, J. Petru, M. Funasako, JS. Koruth, J. Skoda, S. Kralovec, VY. Reddy
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
- MeSH
- časové faktory MeSH
- design vybavení MeSH
- elektrokardiografie ambulantní metody MeSH
- fibrilace síní * chirurgie patofyziologie MeSH
- katetrizační ablace * metody přístrojové vybavení MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- převodní systém srdeční patofyziologie MeSH
- recidiva MeSH
- senioři MeSH
- venae pulmonales * chirurgie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
BACKGROUND: During pulsed field ablation (PFA), electrode-tissue proximity optimizes lesion quality. A novel "single-shot" map-and-ablate spherical multielectrode PFA array catheter that is able to verify electrode-tissue contact was recently studied in a first-in-human trial of atrial fibrillation (AF). OBJECTIVE: The aim of this study was to report lesion durability data, safety, and 12-month effectiveness outcomes. METHODS: The spherical PFA catheter, an all-in-one mapping and ablation system, was used to render anatomy and to deliver biphasic pulses (ungated 1.7 kV pulses; ∼40 seconds/application). Ablation sites included pulmonary veins (PVs) and, in selected patients, posterior wall and mitral isthmus. Follow-up was invasive remapping at ∼3 months, electrocardiograms, Holter monitoring at 6 and 12 months, and symptomatic and scheduled transtelephonic monitoring. The primary and secondary efficacy end points were acute PV isolation (PVI), PVI durability, and atrial arrhythmia recurrence. RESULTS: In the 48-patient AF cohort (paroxysmal, 48%; persistent, 52%), lesion sets included PVI (n = 48; 1.2 applications/PV), posterior wall (n = 20; 3.6 applications/posterior wall), and mitral isthmus (n = 11; 2.9 applications/mitral isthmus). Lesions were acutely successful for all 187 of 187 PVs (100%), 20 of 20 posterior walls (100%), and 10 of 11 mitral isthmuses (91%). Pulse delivery time, left atrial catheter dwell time, and procedure time were 61.5 ± 32.8 seconds, 53.9 ± 26.5 minutes, and 87.8 ± 29.8 minutes, respectively. Remapping (43/48 patients [89.5%]) revealed that 158 of 169 PVs (93.5%) were durably isolated. The only complication was a drug-responsive pericarditis. The 1-year Kaplan-Meier estimates of freedom from atrial arrhythmia were 84.2% (paroxysmal AF) and 80.0% (persistent AF). CONCLUSION: The single-shot spherical array PFA catheter can safely achieve durable lesions, translating into good clinical efficacy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019574
- 003
- CZ-PrNML
- 005
- 20241024110625.0
- 007
- ta
- 008
- 241015s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.hrthm.2024.04.102 $2 doi
- 035 __
- $a (PubMed)38768840
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Turagam, Mohit K $u Icahn School of Medicine at Mount Sinai, New York, New York
- 245 10
- $a AF ablation using a novel "single-shot" map-and-ablate spherical array pulsed field ablation catheter: 1-Year outcomes of the first-in-human PULSE-EU trial / $c MK. Turagam, P. Neuzil, J. Petru, M. Funasako, JS. Koruth, J. Skoda, S. Kralovec, VY. Reddy
- 520 9_
- $a BACKGROUND: During pulsed field ablation (PFA), electrode-tissue proximity optimizes lesion quality. A novel "single-shot" map-and-ablate spherical multielectrode PFA array catheter that is able to verify electrode-tissue contact was recently studied in a first-in-human trial of atrial fibrillation (AF). OBJECTIVE: The aim of this study was to report lesion durability data, safety, and 12-month effectiveness outcomes. METHODS: The spherical PFA catheter, an all-in-one mapping and ablation system, was used to render anatomy and to deliver biphasic pulses (ungated 1.7 kV pulses; ∼40 seconds/application). Ablation sites included pulmonary veins (PVs) and, in selected patients, posterior wall and mitral isthmus. Follow-up was invasive remapping at ∼3 months, electrocardiograms, Holter monitoring at 6 and 12 months, and symptomatic and scheduled transtelephonic monitoring. The primary and secondary efficacy end points were acute PV isolation (PVI), PVI durability, and atrial arrhythmia recurrence. RESULTS: In the 48-patient AF cohort (paroxysmal, 48%; persistent, 52%), lesion sets included PVI (n = 48; 1.2 applications/PV), posterior wall (n = 20; 3.6 applications/posterior wall), and mitral isthmus (n = 11; 2.9 applications/mitral isthmus). Lesions were acutely successful for all 187 of 187 PVs (100%), 20 of 20 posterior walls (100%), and 10 of 11 mitral isthmuses (91%). Pulse delivery time, left atrial catheter dwell time, and procedure time were 61.5 ± 32.8 seconds, 53.9 ± 26.5 minutes, and 87.8 ± 29.8 minutes, respectively. Remapping (43/48 patients [89.5%]) revealed that 158 of 169 PVs (93.5%) were durably isolated. The only complication was a drug-responsive pericarditis. The 1-year Kaplan-Meier estimates of freedom from atrial arrhythmia were 84.2% (paroxysmal AF) and 80.0% (persistent AF). CONCLUSION: The single-shot spherical array PFA catheter can safely achieve durable lesions, translating into good clinical efficacy.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a fibrilace síní $x chirurgie $x patofyziologie $7 D001281
- 650 12
- $a katetrizační ablace $x metody $x přístrojové vybavení $7 D017115
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a venae pulmonales $x chirurgie $7 D011667
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a design vybavení $7 D004867
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a elektrokardiografie ambulantní $x metody $7 D015716
- 650 _2
- $a převodní systém srdeční $x patofyziologie $7 D006329
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a recidiva $7 D012008
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Neuzil, Petr $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Petru, Jan $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Funasako, Moritoshi $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Koruth, Jacob S $u Icahn School of Medicine at Mount Sinai, New York, New York
- 700 1_
- $a Skoda, Jan $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Kralovec, Stepan $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Reddy, Vivek Y $u Icahn School of Medicine at Mount Sinai, New York, New York; Homolka Hospital, Prague, Czech Republic. Electronic address: vivek.reddy@mountsinai.org
- 773 0_
- $w MED00156180 $t Heart rhythm $x 1556-3871 $g Roč. 21, č. 8 (2024), s. 1218-1226
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38768840 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110619 $b ABA008
- 999 __
- $a ok $b bmc $g 2202043 $s 1231547
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 21 $c 8 $d 1218-1226 $e 20240518 $i 1556-3871 $m Heart rhythm $n Heart Rhythm $x MED00156180
- LZP __
- $a Pubmed-20241015
